This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.
A 12 month long-term follow-up study of patients who have achieved complete clearance of AK lesions at the Day 57 in the Phase 3 studies PEP005-016 or PEP005-025.
Study Type
OBSERVATIONAL
Enrollment
117
Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Summarize treatment area recurrence of AK lesions, in the selected treatment area
Time frame: 12 months
Summarize long-term safety data(incidence of AEs in the treatment area)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Burke Pharmaceutical Research
Hot Springs, Arizona, United States
Center for Dermatology
Fremont, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Dermatology Specialists Inc
Oceanside, California, United States
Skin Surgery Medical Group Inc.
San Diego, California, United States
Conant Medical Group
San Francisco, California, United States
North Florida Dermatology Associates, PA
Jacksonville, Florida, United States
University of Miami, Skin Research Camp
Miami, Florida, United States
Atlanta Dermatology, Vein & Research Center, LLC
Alpharetta, Georgia, United States
Medaphase Inc
Newnan, Georgia, United States
...and 32 more locations